Fennec Pharmaceuticals Inc

NASDAQ:FENC  
5.82
+0.04 (+0.69%)
Earnings Announcements

Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results And Provides Business Update

Published: 05/12/2022 10:16 GMT
Fennec Pharmaceuticals Inc (FENC) - Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update.
Q1 Loss per Share $0.14.
Cash and Cash Equivalents Were $18.3 Million As of March 31, 2022.
FDA Prescription Drug User Fee Act (pdufa) Target Action Date Set for September 23, 2022 for Pedmark.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.13

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.14

More details on our Analysts Page.